Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Eli Lilly and Company Inter Partes Review
Case Number:
Case Type:
IPR
Status:
Final Written Decision
Petitioner:
Eli Lilly and Company
Patent Owner:
Tech Center:
-
October 12, 2023
Eli Lilly Continues Migraine IP Wins Over Teva With PTAB Ax
Eli Lilly has persuaded the Patent Trial and Appeal Board to invalidate a Teva Pharmaceuticals patent for the migraine drug Ajovy, shortly after a Massachusetts federal judge overturned a related $176.5 million verdict against Eli Lilly.
-
October 17, 2022
Eli Lilly Gets PTAB To Review More Teva IP On Migraine Drug
The Patent Trial and Appeal Board has agreed to review the validity of a patent on Teva's migraine treatment drug Ajovy, marking the latest development in Teva's battle with Eli Lilly over its competing drug Emgality.